IO Biotech, Inc. Common Stock (IOBT) Stock Price

IOBTStock
$0.00−56.34%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-1.10

IOBT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-116.87%
Price vs S&P 500 (4W)-90.98%
VGM Score28.40

IOBT Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
2.60
2.60
2.50
2.50

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
IOBTIO Biotech, Inc. Common Stock
——D————$0.00
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About IO Biotech, Inc. Common Stock

IO Biotech is a clinical-stage biopharmaceutical company developing cancer vaccines using its proprietary T-win technology platform. The company's approach targets multiple immunosuppressive pathways to enhance the immune system's ability to recognize and attack cancer cells. This dual-pathway targeting strategy aims to overcome a key mechanism by which tumors evade immune response.